(Sharecast News) - Drugmaker Astrazeneca's rare‑disease unit Alexion said on Thursday that Ultomiris had won accelerated US approval as the first treatment aimed at reducing protein levels in the urine of adults with primary IgA nephropathy.
Astrazeneca said the decision followed a priority review by the Food and Dug Administration and...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE